(PharmaNewsWire.Com, January 26, 2018 ) The Branded Generics Market accounted to USD 190.3 billion in 2016 growing at a CAGR of 7.5% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Branded generics are off-patent drugs are bioequivalent to the original product which are marketed under other company’s brand name. the products offer value to patients and healthcare professionals preferring branded drugs.
Increase in the number of patent expiration of branded drugs
Increasing incidences of chronic diseases
Limited availability of generic drugs
Branded Generics Market Segmentation
By formulation type the market for branded generics market is segmented into oral, parental, topical. By therapeutic application the branded generics market is segmented into oncology, cardiovascular, diabetes, neurology, gastrointestinal, dermatology, analgesics and anti-inflammatory.
On the basis of drug class the market is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, others. By category the market is segmented into simple generics, super generics, biosimilars.
On the basis of end-users the branded generics market is segmented into hospital, clinic, and ambulatory center.
On the basis of geography, branded generics market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.
The branded generics market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of branded generics market for global, Europe, North America, Asia Pacific and South America.
Branded Generics Market Major Market Competitors:
Some of the major players operating in branded generics market are Teva Pharmaceutical Industries Ltd., Novartis International AG., Mylan N.V., Abbott Healthcare Pvt Ltd., Actavis pharmaceuticals, Sun Pharmaceutical Industries Limited, Allergan, STADA Arzneimittel, Lupin Pharmaceuticals, Aspen Pharmacare Holding, Dr. Reddy’s, Aurobindo, Cipla, Novartis AG, Pfizer , Eva Pharmaceutical Industries , Abbott Laboratories, Valeant Pharmaceuticals International among others
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
